Saturn V Capital Management LP 13F: Quarter-over-Quarter Portfolio Changes
Saturn V Capital Management LP reported a disclosed portfolio value of approximately $552.2 million in its latest SEC Form 13F-HR filing for Q1 2026, up 1.3% quarter on quarter. Over the quarter, the fund initiated 4 new positions, bought more shares in 10 holdings, trimmed 6 holdings, and exited 3 positions.
Saturn V Capital Management LP's top buy was a new stake in Candel Therapeutics INC (CADL) , equal to 2.6% of the disclosed portfolio. Its top sell was Cogent Biosciences INC (COGT) . The fund sold 48.5% of its previously reported shares, reducing the position's portfolio weight by 3.6 percentage points.
New PositionsQ1 2026
Securities disclosed for the first time in Q1 2026 that were not present in the prior 13F-HR filing.
| Company | Ticker | Initial Portfolio Weight | History |
|---|---|---|---|
| CANDEL THERAPEUTICS INC | CADL | 2.6% | Holders → |
| ZURA BIO LTD | ZURA | 0.8% | Holders → |
| ALTO NEUROSCIENCE INC | ANRO | 0.4% | Holders → |
| SATELLOS BIOSCIENCE INC | MSLE | 0.4% | Holders → |
Top BuysQ1 2026
The fund's top buys among existing positions in Q1 2026. Ranked by portfolio-weight impact, with the percentage of additional shares shown separately.
| Company | Ticker | Portfolio Weight Change | More Shares | History |
|---|---|---|---|---|
| OVID THERAPEUTICS INC | OVID | +0.9% | +66.7% | Holders → |
| DISC MEDICINE INC | IRON | +0.9% | +50.8% | History → |
| INVIVYD INC | IVVD | +-0.9% | +41.5% | Holders → |
| IMMIX BIOPHARMA INC | IMMX | +3.2% | +23.2% | History → |
| X4 PHARMACEUTICALS INC | XFOR | +0.6% | +11.3% | History → |
| MONOPAR THERAPEUTICS INC | MNPR | +-0.5% | +6.1% | Holders → |
| PHARVARIS N V | PHVS | +0.3% | +5.4% | History → |
| VAXCYTE INC | PCVX | +1.9% | +3.2% | History → |
| ALUMIS INC | ALMS | +7.2% | +2.1% | History → |
| INHIBIKASE THERAPEUTICS INC | IKT | +-0.3% | +0.2% | Holders → |
Top SellsQ1 2026
The fund's top sells among positions it retained in Q1 2026. Ranked by portfolio-weight impact. Full exits are listed separately.
| Company | Ticker | Portfolio Weight Change | Shares Sold | History |
|---|---|---|---|---|
| COGENT BIOSCIENCES INC | COGT | -3.6% | 48.5% | Holders → |
| DYNE THERAPEUTICS INC | DYN | -3.2% | 46.0% | Holders → |
| JAZZ PHARMACEUTICALS PLC | JAZZ | -2.2% | 34.3% | History → |
| ABIVAX SA | ABVX | -5.1% | 16.4% | History → |
| CELCUITY INC | CELC | 0.0% | 11.1% | History → |
| AMYLYX PHARMACEUTICALS INC | AMLX | 1.0% | 3.3% | History → |
Full ExitsQ1 2026
Positions present in the prior 13F-HR filing that no longer appear in Q1 2026.
| Company | Ticker | Last-Reported Portfolio Weight |
|---|---|---|
| OCULAR THERAPEUTIX INC | OCUL | 3.4% |
| CENTESSA PHARMACEUTICALS PLC | CNTA | 1.3% |
| INVENTIVA SA | IVA | 0.2% |
Net Portfolio Value ChangeQ1 2026
- $0.5BPrior quarter
- $0.6BCurrent quarter
- +$0.0BNet delta
- +1.3%% change
Methodology & FAQ
How Saturn V Capital Management LP Quarterly Changes Are Computed
All deltas are sourced from sequential SEC Form 13F-HR filings for Saturn V Capital Management LP: each row joins the most recent filing against the immediately preceding quarterly filing for the same fund. Share-count changes reflect reported trading activity, while portfolio weights can also move because of market price changes. Portfolio weights are normalized to exclude listed options for comparability. A complete description — including how confidential treatment filings are handled — is documented in the Methodology.
What stocks did Saturn V Capital Management LP buy in Q1 2026?
In Q1 2026, Saturn V Capital Management LP initiated 4 new positions (CANDEL THERAPEUTICS INC (CADL), ZURA BIO LTD (ZURA), ALTO NEUROSCIENCE INC (ANRO), SATELLOS BIOSCIENCE INC (MSLE)); bought more shares of OVID THERAPEUTICS INC (OVID), DISC MEDICINE INC (IRON), INVIVYD INC (IVVD), IMMIX BIOPHARMA INC (IMMX), X4 PHARMACEUTICALS INC (XFOR) — the largest 5 of 10 adds.
What stocks did Saturn V Capital Management LP sell in Q1 2026?
In Q1 2026, Saturn V Capital Management LP fully sold 3 positions (OCULAR THERAPEUTIX INC (OCUL), CENTESSA PHARMACEUTICALS PLC (CNTA), INVENTIVA SA (IVA)); reduced holdings in COGENT BIOSCIENCES INC (COGT), DYNE THERAPEUTICS INC (DYN), JAZZ PHARMACEUTICALS PLC (JAZZ), ABIVAX SA (ABVX), CELCUITY INC (CELC) — the largest 5 of 6 reductions.
Which positions did Saturn V Capital Management LP initiate in Q1 2026?
Saturn V Capital Management LP established 4 new positions in Q1 2026: CANDEL THERAPEUTICS INC (CADL, 2.6%), ZURA BIO LTD (ZURA, 0.8%), ALTO NEUROSCIENCE INC (ANRO, 0.4%), SATELLOS BIOSCIENCE INC (MSLE, 0.4%).
Which existing positions saw the largest allocation increases for Saturn V Capital Management LP in Q1 2026?
Of 10 existing positions with share-count increases in Q1 2026, the largest were: OVID THERAPEUTICS INC (OVID, +0.9% weight, +66.7% shares), DISC MEDICINE INC (IRON, +0.9% weight, +50.8% shares), INVIVYD INC (IVVD, +-0.9% weight, +41.5% shares), IMMIX BIOPHARMA INC (IMMX, +3.2% weight, +23.2% shares), X4 PHARMACEUTICALS INC (XFOR, +0.6% weight, +11.3% shares), MONOPAR THERAPEUTICS INC (MNPR, +-0.5% weight, +6.1% shares), PHARVARIS N V (PHVS, +0.3% weight, +5.4% shares), VAXCYTE INC (PCVX, +1.9% weight, +3.2% shares), ALUMIS INC (ALMS, +7.2% weight, +2.1% shares), INHIBIKASE THERAPEUTICS INC (IKT, +-0.3% weight, +0.2% shares).
Which positions did Saturn V Capital Management LP fully exit in Q1 2026?
Saturn V Capital Management LP fully exited 3 positions in Q1 2026: OCULAR THERAPEUTIX INC (OCUL, last-reported weight 3.4%), CENTESSA PHARMACEUTICALS PLC (CNTA, last-reported weight 1.3%), INVENTIVA SA (IVA, last-reported weight 0.2%).
Which existing positions saw the largest allocation reductions for Saturn V Capital Management LP in Q1 2026?
Of 6 existing positions with share-count reductions in Q1 2026, the largest were: COGENT BIOSCIENCES INC (COGT, -3.6% weight, -48.5% shares), DYNE THERAPEUTICS INC (DYN, -3.2% weight, -46.0% shares), JAZZ PHARMACEUTICALS PLC (JAZZ, -2.2% weight, -34.3% shares), ABIVAX SA (ABVX, -5.1% weight, -16.4% shares), CELCUITY INC (CELC, 0.0% weight, -11.1% shares), AMYLYX PHARMACEUTICALS INC (AMLX, 1.0% weight, -3.3% shares).
Do quarter-over-quarter 13F allocation changes constitute explicit trading signals?
No. Quarter-over-quarter changes reflect a combination of active trading and market price movement. A weight increase can result from price appreciation alone, without the manager adding shares. Share-count delta is the cleaner indicator of explicit trading activity. All deltas on this page are sourced from sequential SEC Form 13F-HR filings.